These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 7940951)

  • 21. Evaluation of the use of brequinar sodium and cyclosporine combination therapy for preventing rat cardiac allograft rejection.
    Cosenza CA; Cramer DV; Eiras-Hreha G; Cajulis E; Wang HK; Makowka L
    Transplant Proc; 1993 Jun; 25(3 Suppl 2):57-8. PubMed ID: 8516945
    [No Abstract]   [Full Text] [Related]  

  • 22. Immunosuppressive agents: recent developments in molecular action and clinical application.
    Gerber DA; Bonham CA; Thomson AW
    Transplant Proc; 1998 Jun; 30(4):1573-9. PubMed ID: 9636637
    [No Abstract]   [Full Text] [Related]  

  • 23. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro.
    Kahan BD; Gibbons S; Tejpal N; Stepkowski SM; Chou TC
    Transplantation; 1991 Jan; 51(1):232-9. PubMed ID: 1987692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of skin graft rejection in mice by rapamycin: a novel immunosuppressive macrolide.
    Eng CP; Gullo-Brown J; Chang JY; Sehgal SN
    Transplant Proc; 1991 Feb; 23(1 Pt 1):868-9. PubMed ID: 1990708
    [No Abstract]   [Full Text] [Related]  

  • 25. Combined rapamycin and cyclosporine immunosuppression in a porcine renal transplant model.
    Granger DK; Cromwell JW; Canafax DM; Matas AJ
    Transplant Proc; 1996 Apr; 28(2):984. PubMed ID: 8623488
    [No Abstract]   [Full Text] [Related]  

  • 26. [New immunosuppressive drugs in transplantation].
    Surdacka E; Sułowicz W; Surdacki A
    Przegl Lek; 1994; 51(8):347-54. PubMed ID: 7532870
    [No Abstract]   [Full Text] [Related]  

  • 27. The synergistic interactions in vitro and in vivo of brequinar sodium with cyclosporine or rapamycin alone and in triple combination.
    Kahan BD; Tejpal N; Gibbons-Stubbers S; Tu Y; Wang M; Stepkowski S; Chou TC
    Transplantation; 1993 Apr; 55(4):894-900. PubMed ID: 8475566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapamycin and cyclosporine produce synergistic but nonidentical mechanisms of immunosuppression.
    Kimball PM; Kerman RH; Kahan BD
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1027-8. PubMed ID: 1989147
    [No Abstract]   [Full Text] [Related]  

  • 29. The immunosuppressive effect of rapamycin on pancreaticoduodenal transplants in the rat.
    Chen HF; Wu JP; Luo HY; Daloze PM
    Transplant Proc; 1991 Aug; 23(4):2239-40. PubMed ID: 1714651
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparative immunoregulatory effects of rapamycin, FK 506 and cyclosporine on mitogen-induced cytokine production and lymphoproliferation.
    Wu J; Palladino MA; Figari IS; Morris RE
    Transplant Proc; 1991 Feb; 23(1 Pt 1):238-40. PubMed ID: 1703683
    [No Abstract]   [Full Text] [Related]  

  • 31. Sirolimus: a new agent for clinical renal transplantation.
    Kahan BD
    Transplant Proc; 1997; 29(1-2):48-50. PubMed ID: 9123092
    [No Abstract]   [Full Text] [Related]  

  • 32. Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease.
    Meiser BM; Billingham ME; Morris RE
    Lancet; 1991 Nov; 338(8778):1297-8. PubMed ID: 1719321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of cyclosporine, rapamycin and FK 506 the survival following allogeneic bone marrow transplantation.
    Markus PM; Cai X; Selvaggi G; Cooper M; Harnaha J; Fung JJ; Starzl TE
    Transplant Proc; 1991 Dec; 23(6):3232-3. PubMed ID: 1721418
    [No Abstract]   [Full Text] [Related]  

  • 34. Sirolimus in transplantation.
    Stepkowski SM; Tian L; Wang ME; Qu X; Napoli K; Kahan BD
    Arch Immunol Ther Exp (Warsz); 1997; 45(5-6):383-90. PubMed ID: 9437494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modes of action of FK506, cyclosporin A, and rapamycin.
    Morris R
    Transplant Proc; 1994 Dec; 26(6):3272-5. PubMed ID: 7527964
    [No Abstract]   [Full Text] [Related]  

  • 36. Porcine small bowel transplantation with rapamycin-based induction immunosuppression and short-course cyclosporine or FK 506 therapy.
    Cohen DS; Fisher RA; Shapiro JH; Goggins WC; Tawes JW; Mills S; Contos M; Ham JM; Schroeder TJ
    Transplant Proc; 1996 Oct; 28(5):2501-5. PubMed ID: 8907923
    [No Abstract]   [Full Text] [Related]  

  • 37. In vivo immunopharmacology of the macrolides FK 506 and rapamycin: toward the era of rational immunosuppressive drug discovery, development, and use.
    Morris RE
    Transplant Proc; 1991 Dec; 23(6):2722-4. PubMed ID: 1721257
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy of rapamycin in orthotopic small bowel transplantation in the rat.
    Marquet RL; de Bruin RW; Heineman E; Jeekel J
    Transplant Proc; 1993 Aug; 25(4):2695-6. PubMed ID: 8356718
    [No Abstract]   [Full Text] [Related]  

  • 39. A comparison of in vivo responses to cyclosporine, FK506, and rapamycin following allogeneic immune challenge.
    Lorber MI; Wilson JH; Harding MW; Gromkowski S; Marks WH
    Transplantation; 1991 Jul; 52(1):167-70. PubMed ID: 1713364
    [No Abstract]   [Full Text] [Related]  

  • 40. Rapamycin in a porcine renal transplant model.
    Almond PS; Moss A; Nakhleh R; Melin M; Chen S; Salazar A; Shirabe K; Matas A
    Transplant Proc; 1993 Feb; 25(1 Pt 1):716. PubMed ID: 8438452
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.